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Summary Artemisinin-based combination therapy (ACT) is one strategy recommended to increase cure rates
in malaria and to contain resistance to Plasmodium falciparum. In the Maheba refugee settlement,
children aged 5 years or younger with a conﬁrmed diagnosis of uncomplicated falciparum malaria are
treated with the combination of sulphadoxine–pyrimethamine (1 day) and artesunate (3 days). To
measure treatment adherence, home visits were carried out the day after the last treatment dose. Patients
who had any treatment dose left were considered certainly non-adherent. Other patients’ classiﬁcation
was based on the answers to the questionnaire: patients whose caretakers stated the child had received
the treatment regimen exactly as prescribed were considered probably adherent; all other patients were
considered probably non-adherent. Reasons for non-adherence were assessed. We found 21.2% (95%
CI [15.0–28.4]) of the patients to be certainly non-adherent, 39.4% (95% CI [31.6–47.6]) probably
non-adherent, and 39.4% (95% CI [31.6–47.6]) probably adherent. Insufﬁcient explanation by the
dispenser was identiﬁed as an important reason for non-adherence. When considering the use of ACT, the
issue of patient adherence remains challenging. However, it should not be used as an argument against
the introduction of ACT. For these treatment regimens to remain efﬁcacious on a long-term basis, speciﬁc
and locally adapted strategies need to be implemented to ensure completion of the treatment.
keywords malaria, adherence, sulphadoxine–pyrimethamine, artesunate, artemisinin-based
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Introduction
Malaria causes between 300 and 500 million new infec-
tions and kills 1 to 2 million people per year, predomin-
antly among young African children (Bloland 2001; WHO
2001). The number of effective anti-malarials available is
in bleak contrast with the magnitude of the disease (Marsh
1998; White et al. 1999; Trape 2001). Chloroquine efﬁc-
acy against Plasmodium falciparum is declining all through
Africa, and the same is true for sulphadoxine–pyrimeth-
amine (SP), although both drugs are still used as ﬁrst-line
treatment in most African settings (Trape 2001). The
consequences are recrudescence of resistant parasite pop-
ulations, increased mortality and morbidity and higher
transmission rates with a greater risk for epidemics (Price
& Nosten 2001; Trape 2001). One strategy that has
been shown to increase cure rates and decrease the
development of drug resistance is the introduction of
artemisinin-based combination therapy (ACT) (White &
Olliaro 1996; White 1999). In Africa, the large-scale use of
ACT as ﬁrst-line treatment for uncomplicated malaria is
recent and limited: at the time of this writing, artemether
and lumefantrine is used in one province of South Africa,
KwaZulu-Natal and in Zambia; amodiaquine and artesu-
nate is used in Zanzibar and Burundi (Baker & Barnes
2001; Roll Back Malaria 2003).
For the broader use of ACT in the continent to be
successful, several issues need to be addressed (Bloland
et al. 2000). One is related to patient’s treatment adher-
ence (compliance) – the degree to which a patient adheres
to the treatment schedule prescribed – which is determined
by numerous and intertwining factors, such as perception
of disease, acceptance of the treatment, its cost, the
complexity of the schedule, the quality of prescription, or
the patient’s clinical improvement. The consequences of
poor patient adherence are serious: cure rates for patients
who do not complete their treatment are likely to be lower,
and exposure to too low a drug level risks the development
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our knowledge, adherence to ACT has only been studied in
South-East Asia (Na-Bangchang et al. 1997; Shwe et al.
1998).
At the time of our study, the Zambian government was
considering changing the national policy which prescribed
chloroquine as ﬁrst-line, and SP as second-line treatment,
to the introduction of ACT. The Central Board of Health
authorized Me ´decins Sans Frontie `res (MSF) to use the
combination of SP and artesunate (SP/AS) in the Maheba
refugee settlement for the treatment of up to age 5 years.
We studied patient adherence to this combination and
assessed reasons for non-adherence.
Materials and methods
Study area and population
Our study took place in the Maheba refugee settlement,
which has existed since 1971 and is situated in the North-
Western Province of Zambia. Most of the estimated
54 000 refugees come from Angola; others are from
Democratic Republic of Congo, Rwanda and Burundi
(UNHCR 2002). Maheba is divided into eight zones, A to
H. Zone H, where our study took place, has a target
population of about 15 000 refugees, who mainly arrived
after the last upsurge of the Angolan war in 1998. Malaria
is considered Zambia’s highest cause of morbidity and
second highest cause of mortality in children under 5.
Prevalence of resistance of 54% and 26% have been
measured for chloroquine and SP, respectively (NMCC
1999; Bijl et al. 2000). In the health clinic of zone H in
Maheba (clinic H, supported by MSF), in the ﬁrst trimester
of 2002, 35.8% of the outpatient consultations were
due to malaria (unpublished data). In this clinic, since
November 2001, all children aged 5 years and younger,
with a history of fever and for whom the diagnosis of
uncomplicated falciparum malaria is conﬁrmed by a rapid
HRP2 test (Paracheck
 ), are prescribed a unique dose of SP
(25 mg sulphadoxine/kg) on day 0, and 3 days of AS
(4 mg/kg/day)startingonday0.Thedrugsareprovidedfree
of charge. The clinic’s pharmacist dispenses the prescribed
treatment loosely in medication sachets and explains how it
should be taken. The dose of SP, as well as the ﬁrst dose of
AS, are supposed to be taken under supervision at the clinic.
Study objective
The objective of the study was to measure patient
adherence to ACT in children up to age 5 years under
routine conditions of prescription in a refugee settlement.
In order to limit bias as much as possible, a minimum of
interventions was undertaken. Our knowledge of the
routine practices in the health centre, the base for the
assessment tools, was founded on an informal account of
the health staff. In order not to inﬂuence these practices, we
did not look to systematically verify them beforehand.
Design and procedures
During the study period, all children aged 5 years or
younger, who were reported to have received SP/AS during
outpatient consultation hours, were included in the study
and visited at home the day after the last treatment dose
(day 3). Axillary temperature on day 0 and concomitant
treatment prescribed were copied beforehand from the
clinic’s register. In case a child belonged to a household
already visited, the child was excluded from the study, so
that no family was interviewed twice. Apart from the study
team, no one was aware of this visit. At the beginning of
the visit, written informed consent from the patient’s
caretaker was obtained. The patient’s axillary temperature
was taken. A structured questionnaire, translated into the
three languages most frequently used in the clinic’s
catchment area and ﬁeld-tested, was applied to the
caretakers. The questionnaire assessed the intake of AS by
the child, both through spontaneous account and a
systematic review of the intake of every single dose. Under
the assumption that, according to the treatment protocol,
the dose of SP was systematically taken at the clinic,
questions did not refer to the intake of SP. Socio-
demographic information on the patient was collected and
the caretaker’s language, age and education level, the
number of people who spent the night at the house, as well
as, for women, the number of children cared for, were
investigated. The questionnaire was completed by counting
any remaining tablets, both of AS and SP. In case tablets
remained, the caretaker was asked to specify why not all
tablets were given to the child. The team of interviewers
was closely supervised by the study coordinator.
Deﬁnition of adherence
Children whose caretakers showed a medication sachet still
containing AS at the moment of the home visit, were
considered as certainly non-adherent. In case the patient
could not show any medication sachet, or in case the
medication sachet was empty, the answers to the ques-
tionnaire were used to classify the patients: those patients
whose caretaker stated to have given the AS, exactly
following the treatment protocol, were considered
probably adherent; patients were considered probably
non-adherent if, according to the caretaker, the patient
took the AS in any other way than prescribed.
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Without any reference of data related to adherence to the
combination of SP/AS, we assumed a non-adherence of
20%. With a precision of 7%, an a-error of 5%, and after
accounting for 20% loss to follow-up or withdrawal, 149
patients were required.
Pharmacist observations and interviews of caretakers
at the end of the consultation
In order to identify possible factors inﬂuencing adherence,
two additional investigations were carried out. For 1 week
after the adherence assessment, the pharmacist was sys-
tematically observed while explaining the SP/AS prescrip-
tion to the guardians of children of 5 years or below; these
guardians were different from those previously inter-
viewed. A check-list was used to verify what information,
needed to take the treatment correctly, was given: timing of
drug intake, importance of completing the treatment,
asking the caretaker if he or she understood the explan-
ation, observation of the supervised treatment dose. As the
observers stood next to the patient during the explanation,
the pharmacist knew a study was being conducted, but he
was blinded to the purpose of the observation.
During that same week, patient’s caretakers were
systematically interviewed after leaving the pharmacy and
right before leaving the clinic, in order to assess their
understanding of the SP/AS prescription. A short ques-
tionnaire, asking for a spontaneous account on how the
treatment was to be given to the child, followed by a
systematic questioning for each treatment dose, was
completed.
Statistical analysis
Data of the adherence assessment, the pharmacist obser-
vations and the caretaker interviews were double-entered
separately in three different databases and analysed using
Epi Info 6.04dfr (CDC, WHO). Sample characteristics and
patient’s classiﬁcation were described as proportions and
presented with 95% conﬁdence intervals (CI). The associ-
ation between non-adherence and potential risk factors
was investigated, using ﬁrst certain non-adherence as such,
and second certain and probable non-adherence combined
as the outcome; the association was measured through
relative risk (RR) estimates with the 95% CI.
Ethical approval
The study protocol was approved by the Zambian
Research Ethics Committee.
Results
Between 7 and 28 February 2002, 162 children were
treated with the combination SP/AS and thus included in
the study. The median age was 12 months (range: 1–71)
and mean axillary temperature on the day of consultation
was 37.8  C (SD: 1.2) (Table 1). On day 3, the home of 18
patients (11.1%) could not be found. These children were
considered lost to follow-up. Two patients (1.2%) who had
not received the study treatment because of temporary drug
shortage were withdrawn from the study. Consequently, a
total of 142 (87.7%) home visits were held for further
analysis. The majority (95.1%) of the patient’s caretakers
were women and the median age of all caretakers was
28 years (range: 16–49). A median number of four people
stayed at the house the night before the visit (range: 2–11).
The median number of children taken care of by women
the day before the visit was 3 (range: 1–9). More than half
of the caretakers (55.6%) had never attended school at all.
For 110 patients (77.5%) the medication sachet was
shown to the home visitors. Thirty patients (21.2%) were
considered certainly non-adherent, 28 of whom had AS left
in the sachet and two had both AS and SP. For 20 patients
(66.7%) one AS treatment dose remained, for eight
patients (26.7%) two AS doses, and for two patients
(6.6%) three AS doses remained. For these patients with
tablets remaining, 10 caretakers stated to have forgotten,
three to have kept the tablets for the future, one that the
Table 1 Socio-demographic and clinical characteristics of
patients on inclusion
Number Percentage
Nationality (n ¼ 161)
Angolan 154 95.7
Others 7 4.3
Language (n ¼ 162)
Lunda/Luvale 109 67.3
Umbundu 36 22.2
Others 17 10.5
Gender (n ¼ 162)
Male 83 51.2
Female 79 48.8
Age (n ¼ 162)
<2 years 104 64.2
2 years or more 58 35.8
Concomitant treatment (n ¼ 161)
Antipyretic only 136 84.5
Others 25 15.5
Temperature on inclusion ( C) (n ¼ 155)
<37.5 59 38.1
‡37.5 and <39.5 81 52.2
‡39.5 15 9.7
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tablets; seven caretakers did not answer and eight gave still
another reason. A further 56 patients (39.4%) were
probably non-adherent, 46 (82.1%) of whom had taken all
three doses but spread over the ﬁrst 2 days. The remaining
56 patients (39.4%) were considered probably adherent.
(Table 2) Children whose caretakers had received some
education had a signiﬁcantly lower risk to be non-adherent,
both for certain non-adherence as the outcome
(RR ¼ 0.46, 95% CI [0.22–0.95]), and for certain and
probable non-adherence combined (RR ¼ 0.67, 95% CI
[0.50–0.90]). For the latter, the caretakers having the same
mother tongue as the pharmacist had a lower risk to be
non-adherent (RR ¼ 0.46, 95% CI [0.28–0.77]). None of
the other risk factors assessed were found to be signiﬁ-
cantly associated with non-adherence.
During one week (27 February to 5 March 2002), 65
explanations by the clinic’s pharmacist were observed. On
average, the time spent on each explanation was <1 min.
The pharmacist speciﬁed the moment when to take the
three AS doses for all patients. For 64.6% (n ¼ 42), he
asked the caretaker whether or not he or she had
understood his explanation. All patients were given the ﬁrst
dose of AS, together with the SP, to be taken at the health
clinic. However, the pharmacist observed the intake of the
drugs in only 16 cases (24.6%).
During the same period, 74 interviews of caretakers at
the end of the consultation were conducted; for 54 (73.0%)
the pharmacist’s explanations had been observed just
before. At the moment of the interview, 13.7% (n ¼ 10) of
the patients had not taken SP, and 19.2% (n ¼ 14) had not
taken the ﬁrst dose of AS. Moreover, 39.7% (n ¼ 29) of
the caretakers could not state the correct day for each dose
to be given at home. Finally, 10 caretakers (13.7%) stated
they would not give the tablets to the child if the child
would not appear sick anymore.
Discussion
In our setting, certain non-adherence to the combination
SP/AS was 21.2%: there is no doubt that one of ﬁve
patients did not complete the treatment within the set
timeframe of 3 days. Taking into consideration the verbal
account of the caretaker, another 39.4% were classiﬁed as
probably non-adherent. Therefore, non-adherence could be
as high as 60.6% if the certain and probable results are
combined. Weaknesses at the prescription level have been
revealed, showing that an adequate fulﬁlment of this task
should not be taken for granted. The pharmacist did not
explain sufﬁciently the treatment schedule and did not
check the intake of the ﬁrst medication dose at the clinic.
The caretaker had not always understood the treatment
guidelines, a factor that might also be inﬂuenced by his or
her education level or by different mother tongues. As two
different samples were used (in order not to introduce
bias), no conclusions can be drawn with regard to the poor
explanations being the cause of poor adherence in Maheba.
However, the results of both independent assessments
show that the weaknesses at the prescription level might
have played a role in patient adherence. However, the
small sample size of the pharmacist observations and the
caretaker interviews should caution against deﬁnitive
interpretations of these outcomes.
To interpret our results, we looked at studies in Africa
measuring adherence to chloroquine; however, few
studies are available and the lack of a uniform methodo-
logy makes true comparison difﬁcult. We found patient
non-adherence in Maheba was rather high, which might be
explained by several factors. First, a very strict deﬁnition
was used, which inﬂuences the interpretation of our results:
in spite of having ingested all tablets prescribed, patients
were classiﬁed probably non-adherent if the day of intake
was incorrect (different from one dose of AS per day). This
contrasts with the other studies which consider only the
quantity taken, and therefore, in comparison with our
study, underestimate non-adherence (Ejezie et al. 1990;
Yeneneh et al. 1993; Vundule & Mharakurwa 1996;
Okonkwo et al. 2001; Nshakira et al. 2002). Secondly, in
the other studies, better adherence was found in the
intervention groups, among patients receiving pre-pack-
aged drugs, or additional and targeted explanations. When
measuring adherence, these interventions are likely to
account for additional bias as people are automatically
aware of a study taking place. In our study, we tried to
measure treatment adherence while limiting similar bias as
much as possible; no intervention methods were introduced
and people only knew about the study once the treatment
was supposed to be ﬁnished. Thirdly, living conditions in
zone H of the Maheba refugee settlement are precarious.
People represent very different backgrounds, knowledge
and behaviour. While ﬂeeing from violence and war, they
functioned on survival mode often for many years, and did
not have regular access to health care or education. Finally,
although this aspect was not studied in particular, the
Table 2 Proportion of certain and probable (non-)adherence
(n ¼ 142)
Number Percentage 95% CI
Certainly non-adherent 30 21.2 [15.0–28.4]
Probably non-adherent 56 39.4 [31.6–47.6]
Probably adherent 56 39.4 [31.6–47.6]
Total 142 100.0
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marks of timing or dosage of the drugs, might also play a
role in patient non-adherence. All these factors might
explain the fact that non-adherence in Maheba was higher
than expected.
However, looking at the results of the previously cited
studies, non-adherence to chloroquine tablets and/or syrup
varied between 9% and 79% (Ansah et al. 2001; Okonkwo
et al. 2001; Yeboah-Antwi et al. 2001; Agyepong et al.
2002; Nshakira et al. 2002). For still other studies, where
adherence has been assessed as part of Knowledge,
Attitudes and Practices (KAP) or household surveys, non-
adherence ranged from 6.3% to 83% (Deming et al. 1989;
Ejezie et al. 1990; Yeneneh et al. 1993; Slutsker et al. 1994;
Vundule & Mharakurwa 1996). In conclusion, whatever
the method used, our results fall within the same range.
Implications of patient non-adherence with ACT lie both
on individual and public health level. The incomplete
elimination of the parasite exposes the patient to recurrent
malaria attacks, increasing malaria-related morbidity
and mortality. On the community level, it leads to
development of parasite resistance, again augmenting
malaria incidence, morbidity and mortality (Price & Nosten
2001). Methods to improve patient adherence comprise the
use of instructive tools such as posters and videotapes, or
the pre-packaging of tablets (Gomes et al. 1998). They have
been shown to increase patient adherence, but are complex
to implement and often produce limited results. The high
turnover of patients in an African setting such as the
Maheba refugee settlement limits the time spent with each
patient. Increased investment of the health personnel,
building a more constructive relation with the patients,
taking the time to explain treatment schedules, and
systematically making patients repeat the explanations,
might be another solution. In any case, research on new,
straightforward and ﬁeld-adapted strategies is needed.
Conclusion
The use of ACT is one of the strategies in Africa to contain
high resistance levels to anti-malarial drugs. Our study
shows that its implementation should not be taken lightly
and that certain difﬁculties, such as poor patient adher-
ence, cannot be ignored. Poor adherence should not serve
as an argument against the introduction of ACT, in the
same way it was never drawn on to stop using chloroquine,
in use for over 50 years. However, investment to improve
patient adherence should be inherently related to initiating
combination therapy. Once combination therapy is put
well into place, adherence to the treatment should be
monitored. The currently used but increasingly ineffective
malaria drugs are likely to be replaced by more complex
treatment schedules. If we want to give a chance to the few
alternatives available for the treatment of malaria, and
ensure treatment efﬁcacy for the coming years, the
improvement of adherence is essential and needs to be
addressed – as from today.
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